By RNAi-mediated knockdown of NF-κB pathway components, EGFR-mutant lung cancer cells became more sensitive to erlotinib; similar outcomes were obtained with pharmacologic inhibition of NF-Κb (498). This evidence concerns the gene EGFR and lung carcinoma.